Lindheimer M D
Department of Obstetrics and Gynecology, University of Chicago, Ill.
Hypertension. 1993 Jul;22(1):127-37. doi: 10.1161/01.hyp.22.1.127.
High blood pressure, which complicates approximately 10% of all pregnancies, remains a major cause of morbidity and mortality for both mother and fetus. A relative paucity of investigative data, as well as the frequent difficulty in making an etiological diagnosis by clinical criteria alone, may be among the reasons why there are many conflicts about the management of hypertension during pregnancy. This clinical conference summarizes current concepts regarding the hypertensive disorders of gestation, focusing on the most dangerous cause, preeclampsia-eclampsia. It further highlights a recent report of the Working Group on High Blood Pressure in Pregnancy convened by the National High Blood Pressure Education Program at the National Heart, Lung, and Blood Institute (the Consensus Report). Among the Working Group's most interesting recommendations in controversial areas were a return to the classification schema suggested by the American College of Obstetricians and Gynecologists in 1972, use of the fifth Korotkoff sound to determine diastolic blood pressure levels, and institution of treatment with antihypertensive drugs for sudden elevations of blood pressure near term to diastolic levels greater than or equal to 105 mm Hg or for levels of 100 mm Hg or higher in pregnant women with chronic hypertension. The Consensus Report further recommended parenteral hydralazine and methyldopa as the drugs of choice for the acute hypertensive crisis and management of chronic hypertension, respectively, based on the long histories of safe use of these agents in gravidas. Parenteral magnesium sulfate remained the preferred therapeutic approach for avoiding or treating the convulsive complication, eclampsia, but the Working Group underscored the need for controlled trials of magnesium's efficacy. Finally, they noted that diuretics should be avoided in preeclampsia, but that these drugs can be continued during gestation if taken before conception, and may be prescribed to pregnant women with chronic hypertension who appear overly salt sensitive.
高血压使约10%的妊娠情况复杂化,仍然是孕产妇和胎儿发病及死亡的主要原因。调查数据相对较少,以及仅根据临床标准进行病因诊断时常常遇到困难,可能是妊娠期间高血压管理存在诸多争议的原因之一。本次临床会议总结了当前关于妊娠高血压疾病的概念,重点关注最危险的病因——子痫前期 - 子痫。会议还进一步强调了由美国国立心肺血液研究所国家高血压教育计划召集的妊娠高血压工作组的最新报告(共识报告)。在有争议的领域,工作组最有趣的建议包括回归美国妇产科医师学会1972年提出的分类方案,使用柯氏音第5时相来确定舒张压水平,以及对于孕晚期舒张压突然升高至大于或等于105 mmHg或慢性高血压孕妇血压达到100 mmHg或更高时开始使用抗高血压药物治疗。共识报告还分别推荐静脉注射肼屈嗪和甲基多巴作为急性高血压危象和慢性高血压管理的首选药物,这是基于这些药物在孕妇中长期安全使用的历史。静脉注射硫酸镁仍然是预防或治疗惊厥并发症子痫的首选治疗方法,但工作组强调需要对镁的疗效进行对照试验。最后,他们指出子痫前期应避免使用利尿剂,但如果在受孕前就已服用,这些药物在妊娠期间可以继续使用,并且可以开给对盐过度敏感的慢性高血压孕妇。